Articles tagged with Steatohepatitis
Researchers found inhibiting ACMSD increases NAD+ levels, reducing inflammation and fibrosis in mouse models of MASLD/MASH. Boosting NAD+ production could protect against severe liver damage and cirrhosis.
Researchers explore antidiabetic agents, PPAR agonists, FXR agonists, and other novel compounds to target MASLD pathogenesis. Combination therapies may enhance therapeutic efficacy while minimizing side effects, offering new hope to patients at risk of advanced liver disease.